Anti-HIV protease抗体[1696] (ab8327)
Key features and details
- Mouse monoclonal [1696] to HIV protease
- Suitable for: Dot blot
- Isotype: IgG1
概述
-
产品名称
Anti-HIV protease抗体[1696]
参阅全部 HIV protease 一抗 -
描述
小鼠单克隆抗体[1696] to HIV protease -
宿主
Mouse -
特异性
The antibody recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2). The antibody does not react with the precursor.
-
经测试应用
适用于: Dot blotmore details -
免疫原
Recombinant full length protein corresponding to HIV protease. Bacterially expressed full-length HIV-1 protease.
Database link: P03366
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.40
Preservative: 0.098% Sodium azide
Constituent: 99% PBS -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
1696 -
骨髓瘤
unknown -
同种型
IgG1 -
研究领域
相关产品
-
Compatible Secondaries
应用
应用 | Ab评论 | 说明 |
---|---|---|
Dot blot |
Use at an assay dependent concentration.
|
说明 |
---|
Dot blot
Use at an assay dependent concentration. |
靶标
-
相关性
The HIV1 core consists of a viral genome housed within a conical viral capsid that is generated during virion maturation. Human immunodeficiency virus type 1 (HIV1) matures after the viral protease processes the Gag and Pol polyproteins at 10 substrate locations. The protease of HIV1 is an aspartic protease and is functional only as a dimer; dimerization results in the formation of a binding cleft in which each of the two catalytic aspartic acids in which each monomer contributes each of the 2 catalytic aspartic acids. Because the protease is active only as a dimer, two of the GagPol precursors must themselves dimerize during virus assembly so that their protease domains can dimerize, become active, and process the precursors. Both the order and kinetics of cleavage as well as the extent of precursor processing appear to be critical steps in the generation of fully infectious, appropriately assembled viral particles. Inhibition of HIV-1 protease represents an important avenue for antiviral therapy. Currently available combination chemotherapy with reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) for human immunodeficiency virus type 1 (HIV1) infection and AIDS have been shown to suppress the replication of HIV1 and extend the life expectancy of HIV1 infected individuals. -
别名
- HIV-1 protease antibody
- Human immunodeficiency virus protease antibody
- PR antibody
- Retropepsin antibody
图片
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
数据表及文件
-
SDS download
-
Datasheet download
文献 (8)
ab8327 被引用在 8 文献中.
- Yu FH et al. Amino acid substitutions at the HIV-1 transframe region significantly impair virus infectivity. PLoS One 17:e0262477 (2022). PubMed: 35085286
- Han S et al. Continuous progression of hemorrhage of sphenoid ridge meningioma causing cerebral hernia: A case report and literature review. Oncol Lett 20:785-793 (2020). PubMed: 32566005
- Polyzos AA et al. Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice. Cell Metab 29:1258-1273.e11 (2019). PubMed: 30930170
- Matsunaga S et al. A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors. Front Microbiol 6:1220 (2015). WB . PubMed: 26583013
- Lin PH et al. Slow immunological progression in HIV-1 CRF07_BC-infected injecting drug users. Emerg Microbes Infect 2:e83 (2013). WB . PubMed: 26038447
- O'loughlin TL et al. Diversification and Specialization of HIV Protease Function During In Vitro Evolution. Mol Biol Evol 23:764-72 (2006). WB . PubMed: 16423863
- M'Barek NB et al. HIV-2 Protease resistance defined in yeast cells. Retrovirology 3:58 (2006). WB . PubMed: 16956392
- Lescar J et al. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci 8:2686-96 (1999). PubMed: 10631984